Q-omics provides the consensus-scored CTAG2 profile across patient tissues and cancer cell-line models. CTAG2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, CTAG2 is differentially expressed in 6, with the highest sampling consensus in LIHC. Additionally, CTAG2 RNA expression shows 6,766 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, LIHC, and TGCT as cancer lineages where CTAG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTAG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTAG2 survival associations across molecular data types. CTAG2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTAG2 RNA expression–survival associations across cancer types. High CTAG2 expression shows unfavorable associations in UCEC, COAD, UCS, KIRP and BLCA, but favorable associations in PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .020). Together, the overview and detailed table identify UCEC as the clearest survival context for CTAG2 RNA expression.
This table summarizes CTAG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for CTAG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTAG2 shows higher tumor expression in LIHC, BLCA, LUSC, HNSC, LUAD and STAD. The LIHC box plot shows higher CTAG2 RNA expression in tumor versus normal tissue (log2 FC = +1.255, t-test p < 0.001).
This table shows molecular features associated with CTAG2 in patient tissues and cancer cell lines. In patient samples, CTAG2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CTAG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Myeloma.
